RxDoctor Payments Data

Archana Asundi, MD

Infectious Disease · Boston, MANPI 1417319013

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,710 of the $10,657 with a category attached, or 72.3%. Gilead accounts for 99.3% of it on its own, with 1 other manufacturer making up the rest.

$10,657in general payments, 2019–2025

Across 25 payments — averaging $426.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$11K
  • Theratechnologies Inc.$80
$456,508in research payments, 2019–2025

Across 125 payments — averaging $3652.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Theratechnologies Inc.$221K
  • Viiv Healthcare Company$98K
  • Gilead$95K
  • GSK$41K

What the payments were for

  • Consulting fees$7,71072%
  • Travel & lodging$2,13620%
  • Food & beverage$7687%
  • Education$440%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead23$10,577
Theratechnologies Inc.2$80

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,657 in reported general payments places this provider in the 85th percentile of 368 infectious disease providers in Massachusetts.

See all infectious disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$7,831
Medicare patients
35
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala133$499,686
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$117,354
PrezcobixDarunavir/Cobicistat47$110,214
GenvoyaElviteg/Cob/Emtri/Tenof Alafen20$76,190
TivicayDolutegravir Sodium35$75,999
JulucaDolutegravir/Rilpivirine20$70,611
DescovyEmtricitabine/Tenofov Alafenam16$36,920
Atazanavir Sulfate12$1,594
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$859
Rosuvastatin Calcium42$747
ValacyclovirValacyclovir Hcl23$567
Losartan Potassium25$294
Atorvastatin Calcium55$276
Amlodipine Besylate40$223
Spironolactone16$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$10,577$612,797169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 infectious disease providers in Massachusetts.

Other infectious disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →